BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma

Xu,Meng; Liu,Qingquan; Jia,Yuli; Tu,Kangsheng; Yao,Yingmin; Liu,Qingguang; Guo,Cheng

doi:10.3892/ol.2016.4969

BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma

Authors:
- Meng Xu
- Qingquan Liu
- Yuli Jia
- Kangsheng Tu
- Yingmin Yao
- Qingguang Liu
- Cheng Guo
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: August 8, 2016 https://doi.org/10.3892/ol.2016.4969
Pages: 2648-2656
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Branched‑chain amino acid transaminase 1 (BCAT1) has been associated with numerous types of tumors; however, few previous studies have evaluated the expression and role of BCAT1 in hepatocellular carcinoma (HCC). In the present study, the expression of BCAT1 was detected by reverse transcription‑quantitative polymerase chain reaction and immunoblotting in six HCC cell lines and 74 pairs of HCC and adjacent non‑cancerous liver tissues. In addition, the correlation between the expression levels of c‑Myc and BCAT1 was analyzed using immunohistochemistry. Furthermore, RNA silencing was performed using c‑Myc‑specific or BCAT1‑specific small interfering RNA, after which wound healing and Transwell cell invasion assays were performed. Finally, the clinicopathological characteristics of BCAT1 in patients with HCC were analyzed. It was shown that the expression of BCAT1 was significantly higher in HCC tissues compared with adjacent non‑tumor tissues (P<0.001), and in HCC cell lines compared within the L‑02 hepatic cell line (P<0.001). In addition, immunohistochemical analyses indicated that the expression of BCAT1 was positively correlated with c‑Myc (r=0.706, P<0.001). BCAT1 expression was shown to be downregulated in c‑Myc‑knockdown cells, and silencing of BCAT1 expression reduced the invasion and migration of HCC cells. Furthermore, a clinical analysis indicated that BCAT1 expression in HCC tissues was significantly associated with the tumor‑node‑metastasis stage, tumor number and tumor differentiation (all P<0.05), and that BCAT1 was able to predict the 5‑year survival and disease‑free survival rates of patients with HCC (both P<0.001). The results of the present study suggested that BCAT1 expression is upregulated in patients with HCC, and that BCAT1 may serve as a potential molecular target for the diagnosis and treatment of HCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB, Davila JA, Petersen NJ and McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med. 139:817–823. 2003. View Article : Google Scholar : PubMed/NCBI
3	Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W and Taylor-Robinson SD: Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 3:353–367. 2009. View Article : Google Scholar : PubMed/NCBI
4	Dhanasekaran R, Limaye A and Cabrera R: Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 4:19–37. 2012.PubMed/NCBI
5	Zheng X, Song T, Dou C, Jia Y and Liu Q: CtBP2 is an independent prognostic marker that promotes GLI1 induced epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget. 6:3752–3769. 2015. View Article : Google Scholar : PubMed/NCBI
6	Yoshikawa R, Yanagi H, Shen CS, Fujiwara Y, Noda M, Yagyu T, Gega M, Oshima T, Yamamura T, Okamura H, et al: ECA39 is a novel distant metastasis-related biomarker in colorectal cancer. World J Gastroenterol. 12:5884–5889. 2006. View Article : Google Scholar : PubMed/NCBI
7	Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G and Benvenisty N: ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Proc Natl Acad Sci USA. 93:7143–7148. 1996. View Article : Google Scholar : PubMed/NCBI
8	Eden A and Benvenisty N: Involvement of branched-chain amino acid aminotransferase (Bcat1/Eca39) in apoptosis. FEBS Lett. 457:255–261. 1999. View Article : Google Scholar : PubMed/NCBI
9	Bledsoe RK, Dawson PA and Hutson SM: Cloning of the rat and human mitochondrial branched chain aminotransferases (BCATm). Biochim Biophys Acta. 1339:9–13. 1997. View Article : Google Scholar : PubMed/NCBI
10	Eden A, Simchen G and Benvenisty N: Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. J Biol Chem. 271:20242–20245. 1996. View Article : Google Scholar : PubMed/NCBI
11	Zhou W, Feng X, Ren C, Jiang X, Liu W, Huang W, Liu Z, Li Z, Zeng L, Wang L, et al: Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma. Mol Cancer. 12:532013. View Article : Google Scholar : PubMed/NCBI
12	Bible E: Neuro-oncology: BCAT1 promotes cell proliferation in aggressive gliomas. Nat Rev Neurol. 9:4202013. View Article : Google Scholar : PubMed/NCBI
13	Zerban H, Radig S, Kopp-Schneider A and Bannasch P: Cell proliferation and cell death (apoptosis) in hepatic preneoplasia and neoplasia are closely related to phenotypic cellular diversity and instability. Carcinogenesis. 15:2467–2473. 1994. View Article : Google Scholar : PubMed/NCBI
14	Tönjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai AH, Karra D, Piro RM, et al: BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med. 19:901–908. 2013. View Article : Google Scholar : PubMed/NCBI
15	Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, et al: Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 294:G1281–G1287. 2008. View Article : Google Scholar : PubMed/NCBI
16	Matsumura T, Morinaga Y, Fujitani S, Takehana K, Nishitani S and Sonaka I: Oral administration of branched-chain amino acids activates the mTOR signal in cirrhotic rat liver. Hepatol Res. 33:27–32. 2005. View Article : Google Scholar : PubMed/NCBI
17	Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, et al: Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C. Gastroenterology. 141:128–140, 140.e1-e2. 2011. View Article : Google Scholar : PubMed/NCBI
18	Ben-Yosef T, Yanuka O, Halle D and Benvenisty N: Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene. 17:165–171. 1998. View Article : Google Scholar : PubMed/NCBI
19	Ben-Yosef T, Eden A and Benvenisty N: Characterization of murine BCAT genes: Bcat1, a c-Myc target, and its homolog, Bcat2. Mamm Genome. 9:595–597. 1998. View Article : Google Scholar : PubMed/NCBI
20	Peng SY, Lai PL and Hsu HC: Amplification of the c-myc gene in human hepatocellular carcinoma: Biologic significance. J Formos Med Assoc. 92:866–870. 1993.PubMed/NCBI
21	Liu Q, Tu K, Zhang H, Zheng X, Yao Y and Liu Q: TPX2 as a novel prognostic biomarker for hepatocellular carcinoma. Hepatol Res. 45:906–18. 2015. View Article : Google Scholar : PubMed/NCBI
22	Edmondson HA and Steiner PE: Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer. 7:462–504. 1954. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Colombo M and Sangiovanni A: Treatment of hepatocellular carcinoma: Beyond international guidelines. Liver Int. 35(Suppl 1): S129–S138. 2015. View Article : Google Scholar
25	Bruix J and Sherman M: American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
26	Roberts LR and Gores GJ: Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Semin Liver Dis. 25:212–225. 2005. View Article : Google Scholar : PubMed/NCBI
27	Scaggiante B, Kazemi M, Pozzato G, Dapas B, Farra R, Grassi M, Zanconati F and Grassi G: Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol. 20:1268–1288. 2014. View Article : Google Scholar : PubMed/NCBI
28	Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S and Yamada T: Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res. 16:2518–2528. 2010. View Article : Google Scholar : PubMed/NCBI
29	Schattenberg JM, Schuchmann M and Galle PR: Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol. 26(Suppl 1): S213–S219. 2011. View Article : Google Scholar
30	Elsemman IE, Mardinoglu A, Shoaie S, Solima TH and Nielsen J: Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism. Mol Biosyst. 12:1496–1506. 2016. View Article : Google Scholar : PubMed/NCBI